Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

Objective To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody)
with molnupiravir (an antiviral) in preventing severe outcomes of covid-19 in adult patients …

This network meta-analysis compared the clinical efficacy and safety of anti-viral agents for
the prevention of disease progression among non-hospitalized patients with COVID-19 …

The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

ABSTRACT Introduction Soft mist inhalers (SMIs) are propellant-free inhalers that utilize
mechanical power to deliver single or multiple doses of inhalable drug aerosols in the form …

Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Background Remdesivir and sotrovimab both have clinical trial data in the outpatient setting
demonstrating reduction in the risk of hospitalizations and emergency department (ED) visits …